Source: NY Times
The FDA just approved the first drug treatment for a severe form of multiple sclerosis, a disease that affects the brain and spinal cord.
The treatment called Ocrevus, Genentech, has been found to “halt progression of the disease” in patients with relapsing multiple sclerosis. The effects are less prominent for patients with more severe forms of the disease, researchers say.
The drug would cost $65,000 a year – about 25 percent less than a current drug that has been proven to be less successful, New York Times reported. In addition, the side effects of the drug are less severe than for other existing drugs on the market.
Read full story: NY Times